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There is evidence that obesity related disorders are increased among people with 
depression. Variation in the FTO (fat mass and obesity associated) gene has been shown 
to contribute to common forms of human obesity. This study aimed to investigate the 
genetic influence of polymorphisms in FTO in relation to Body Mass Index (BMI) in two 
independent samples of major depressive disorder (MDD) cases and controls. 
We analysed 88 polymorphisms in the FTO gene in a clinically ascertained sample of 
2442 MDD cases and 809 controls (Radiant Study). Eight of the top 10 SNPs showing 
the strongest associations with BMI were followed-up in a population-based cohort 
(PsyCoLaus Study) consisting of 1292 depression cases and 1690 controls. 
Linear regression analyses of the FTO variants and BMI yielded 10 SNPs significantly 
associated with increased BMI in the depressive group but not the control group in the 
Radiant sample. The same pattern was found in the PsyCoLaus sample. We found a 
significant interaction between genotype and affected status in relation to BMI for 7 
SNPs in Radiant (p<0.0057), with PsyCoLaus giving supportive evidence for 5 SNPs (p-
values between 0.03-0.06) which increased in significance when the data were combined 
in a meta-analysis.   
This is the first study investigating FTO and BMI within the context of MDD, and the 
results indicate that having a history of depression moderates the effect of FTO on BMI.  
This finding suggests that FTO is involved in the mechanism underlying the association 
between mood disorders and obesity. 
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Introduction 
In addition to unipolar major depressive disorder (MDD) being a major public health 
problem in its own right1 there is growing evidence suggesting that rates of physical 
disease, such as obesity and diabetes, are elevated amongst people with depression.2,3 The 
study by Farmer et al. demonstrated a striking relationship between recurrent clinically 
sampled depression and increased BMI, type II diabetes, coronary heart disease and 
hypertension. Regression analyses showed that the association of depression with this 
cluster of disorders (sometimes referred to a ‘metabolic syndrome’) was largely 
accounted for BMI.2 A recent World Health Survey (WHS) study involving 245404 
participants from 60 countries in regions all over the world found that the number of 
participants with one or more chronic physical disease, and comorbid depression, ranges 
from 9.3 to 23%.3 Furthermore, recent studies support the hypothesis that there may be 
shared aetiological factors, including genetic factors, between recurrent unipolar 
depression, obesity and physical disorders.2,4 
 
The fat mass and obesity associated gene, FTO, on chromosome 16q has been reported 
multiple times to contribute to common forms of human obesity.5 In 2007, two groups 
independently identified a common single nucleotide polymorphism (SNP) in FTO 
(rs9939609) that was associated with BMI and an increased risk for adult obesity.6,7 In 
the same year, a third group performing a genome-wide association (GWA) study of BMI 
also found variants in FTO  strongly associated with BMI and obesity-related traits.8  
Recently the FTO association with BMI has also been replicated in two large GWA 
studies for obesity.9,10 These two studies strongly support the association between FTO 
variants and obesity. 
 
Animal studies reported that FTO is widely expressed in the brain, with high expression 
in hypothalamic nuclei regulating energy balance.11 Human studies have also found that 
the FTO variant (rs9939609) risk allele is associated with an increased energy intake12,13 
and diminished satiety,14 implicating FTO in the regulation of appetite. 
 
This study explores the hypothesis that shared genetic aetiological factors exist between 
depression and obesity. Specifically, we aimed to investigate the influence of 
polymorphisms in FTO in relationship with BMI on a sample of depressed patients and 
psychiatrically healthy controls and follow-up the SNPs showing the strongest 
associations in an independent population-based cohort.  
 
Materials and methods 
Clinical Sample 
1. Radiant Study 
The depression case sample included 2442 individuals (740 men, 1702 women; mean age 
± s.d.: 45.25±12.15) and was sourced from several studies: the Depression Case-Control 
(DeCC) study15, Depression Network (DeNT) study16,17 and the Genome Based 
Therapeutic Drugs for Depression (GENDEP) study.18 The DeCC sample comprises 
subjects with recurrent unipolar depression (minimum two episodes) of at least moderate 
severity as defined by DSM-IV or ICD-10 criteria, recruited from three UK sites 
(London, Cardiff and Birmingham).15 Probands from the DeNT affected sibling pair 
linkage study consisting of cases with recurrent unipolar depression of at least moderate 
severity collected at seven European sites and one US site.16,17 The GENDEP study 
includes individuals with an episode of depression of at least moderate severity recruited 
from nine European centres,18 not necessarily recurrent. Either DSM-IV or ICD-10 
diagnosis of depression were ascertained using the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) interview in all three studies.19 Individuals were excluded if 
they, or a first-degree relative, had a history of mania, hypomania, schizophrenia or 
bipolar disorder, or if the depression occurred in relation to alcohol, substance misuse or 
a medical illness or medication.  
 
Eight hundred and nine control individuals from the UK (313 men, 496 women; mean 
age ± s.d.: 39.9±13.71) were screened for lifetime absence of any psychiatric disorder 
using a modified version of the Past History Schedule.20 Participants were excluded if 
they, or a first-degree relative, ever fulfilled the criteria for depression, bipolar disorder or 
schizophrenia or if they scored 10 or above on the Beck Depression Inventory.21 
All cases and controls were of white European ancestry. 
 
2. PsyCoLaus Study 
The sample is part of the PsyCoLaus study which focused on psychiatric symptoms in a 
population-based cohort originally assessed for cardiovascular risk factors (CoLaus). 
CoLaus is a cross-sectional study including 6188 extensively phenotyped Caucasian 
individuals randomly selected from the list of residents of the city of Lausanne 
(Switzerland). All 35 to 66 year-old subjects of the CoLaus sample were invited to 
participate in the psychiatric evaluation for the PsyCoLaus sub-study (see22,23 for a 
detailed description). The PsyCoLaus sample included 1296 cases (431 men, 862 women; 
mean age ± s.d.: 49.69±8.68) who fulfilled lifetime ever criteria for MDD according to 
DSM-IV based on assessment using the Diagnostic Interview for Genetics Studies 
(DIGS24). The 1690 PsyCoLaus subjects (974 men, 724 women; mean age ± s.d.: 
50.59±8.94) who have never fulfilled criteria for MDD were included as controls. 
 
All studies were approved by the local ethical committees and informed written consent 
was obtained from all participants. 
Table 1 summarizes the characteristics of the subjects in both studies. 
 
Phenotypic data 
Body Mass Index (BMI) was defined as weight (kilograms) / height (metres)2. In the 
Radiant study self-reported height and weight were obtained during the SCAN interview 
for cases and during telephone interview for controls. In the PsyCoLaus sample weight 
and height were measured with participants standing without shoes in light indoor 
clothes.22 In both samples the distribution of BMI was positively skewed. We therefore 





1. Radiant Study 
Depression cases and controls were genotyped using the Illumina HumanHap610-Quad 
BeadChips by the Centre National de Génotypage (CNG) as previously described.25 After 
applying stringent quality control criteria for missing genotypes, departure from Hardy-
Weinberg equilibrium and low minor allele frequency, a total of 88 SNPs spanning FTO 
(+/- 20 Kb either side, chr16: 52,295,376-52,705,882. UCSC Mar.2006) were included in 
the analyses. 
 
2. PsyCoLaus Study 
Genotyping for depressive cases and controls was performed using the Affymetrix 500 K 
SNP chip. The genotyping are described in detail in the CoLaus22 and PsyCoLaus23 
studies. IMPUTE v0.2 was used to impute the SNPs used in the Radiant study based on 
the HapMap CEU (Phase II, release 21) population. 
 
Statistical analyses 
T-Test analyses were carried out to test the association between BMI and affected status 
in both studies. 
In Radiant study linear regression models for quantitative traits assuming an additive 
genetic model were performed for each SNP to test for association between LogBMI and 
FTO variants. The analyses were first carried out in the whole sample and then separately 
in the depressive cases and controls. Following the same procedures the most significant 
SNPs associated with LogBMI in the Radiant sample were analysed in PsyCoLaus. 
Affected status, gender and age were included as covariates in the regression analyses in 
both studies. Principal components were used to control for possible population 
stratification. In the Radiant study we included centre of ascertainment as a covariate. We 
also tested for the interaction between FTO polymorphisms and affected status for an 
effect on LogBMI.  
 
The number of effective/independent tests in the Radiant data was calculated using the 
method of Galwey et al.26 The significance was assessed by dividing 0.05 by the number 
of effective tests (calculated to be 44.8115), giving threshold of p< 0.0011.  
 
The statistical analyses were performed using the statistical package PLINK v1.0627 and 
the software Quicktest28 in the Radiant and PsyCoLaus studies, respectively. 
 
Since the most strongly associated FTO polymorphism reported in literature so far is 
rs9939609, we used Beagle29 to impute the genotypes for this SNP in the UK subsample 
of the Radiant study (1361 cases; 813 controls) using HapMap CEU samples as a 
reference panel. Two genotyped SNPs (rs8050136, rs3751812) are in absolute linkage 
disequilibrium (LD) (r2=1) with rs9939609, allowing imputation with high certainty. (For 
LD structure of the variants most significantly associated see supplementary Figure 1). 
Analysis of imputed data was performed using gene dosage values. The regression 
analyses with the imputed variant were performed using R software. 
 
Finally, we performed an interaction analysis between the most significant SNPs 




BMI and Depressive status 
In Radiant, as previously reported in a subset of the same data2, there was a significant 
association between BMI and affected status. Depressed patients had significantly higher 
BMI values in comparison with controls in both men and women (Men: t=-5.049, 
p=0.007; Women: t=-8.755, p<0.0001). These results differ in the PsyCoLaus sample 
where there were no significant differences in BMI values between depressed cases and 
controls (Men: t=-1.57, p=0.117; Women: t=-0.11, p=0.913) (Table 1).  
 
FTO and LogBMI 
All SNPs tested were in Hardy Weinberg Equilibrium (Radiant: p> 0.01; PsyCoLaus: p> 
10-4) in depressive cases and controls. 
1. Radiant Study 
Following linear regression between the 88 FTO polymorphisms and LogBMI, 9 of these 
SNPs located in the first intron of the gene were the most significantly associated with 
BMI using affected status, gender, age and principal components as covariates. Although 
these SNPs are mainly in high LD with each other (Figure 1), conditional analyses 
conducted on the most significant SNP (rs3751812) suggested that they represent two 
independent signals. One signal includes SNPs rs7205986 and rs6499640, and the second 
signal includes the rest of the SNPs. Linear regression carried out with the imputed 
rs9939609 SNP in the UK subsample, also correcting for affected status, gender, age and 
principal components yielded a significant association with LogBMI (ß=-0.006, 
p=0.0149). 
 
Linear regression in the depressive group with gender, age, principal components and 
study as covariates presented evidence of association for the same 9 SNPs that were 
associated with LogBMI in the combined sample. Moreover, the association between 
these SNPs and BMI was stronger when analysing the depressive group alone versus the 
combined sample. Seven remained statistically significant following multiple testing 
correction (see Table 2).   
 
None of the SNPs tested for association between FTO and LogBMI reached significant p-
values in the control group alone. Results for the combined, case and control analyses are 
shown in Figure 1. 
 
Controlling for gender, age and principal components, rs9939609 was associated with 
LogBMI in the depressive group (ß=-0.011, p=0.0007) but not in the control group 
(ß=0.003, p=0.39). 
 
2. PsyCoLaus Study 
Eight of the top 10 SNPs associated with BMI in the Radiant study had very high 
imputation accuracy (rSqHat > 0.9) and were included in association analyses. Linear 
regression analyses in combined depressive cases and controls yielded 6 SNPs 
significantly associated with LogBMI when affected status, gender, age and principal 
components were used as covariates. Results carried out in the depressive group alone 
with gender, age and principal components co-varied in the regression model yielded the 
same 6 SNPs significantly associated with LogBMI (Table 3). As in the Radiant study, 
the analyses in the control group alone showed no significant associations with logBMI 
(Table 3). 
 
Interaction between FTO and affected status 
1. Radiant Study 
We found a significant interaction between genotype and affected status in relationship to 
LogBMI, and found no significant interaction with gender (data not shown). An 
interaction between genotype and affected status was observed in 7 SNPs (p<0.0057) 
(Table 2).  
We also found an interaction between the previously reported rs9939609 (the 
polymorphism most commonly associated with BMI in previous studies) and affected 
status in the UK Radiant subsample (ß=-0.01, p=0.0047) taking gender, age and principal 
components as covariates in the model. 
 
2. Radiant and PsyCoLaus combined analysis 
Five of the seven SNPs with high imputation quality genotypes in PsyCoLaus, showed     
evidence (p-values between 0.03-0.06) of interaction between genotype and MDD 
affected status in their effect on LogBMI (Table 3). Additionally, these SNPs were 
statistically significant in a meta-analysis of both cohorts (Table 4). The Cochran Q p-
values from the test of heterogeneity of effects in each cohort were non significant 
indicating that estimates were similar across the two cohorts and justifying the effects 
meta-analysis (data not shown). 
 
Discussion 
We have investigated the influence of variants in FTO on BMI in a large clinical sample 
of depressed patients and controls (Radiant) to explore the genetic mechanism underlying 
the reported association between BMI or obesity and psychiatric disorders.30-32 We have 
then followed up our findings in a population-based cohort (PsyCoLaus).We found 
associations between several SNPs in FTO and BMI that are in keeping with previous 
reports. However an intriguing novel finding in the Radiant sample is that the association 
observed in the whole sample could be attributed to the depressive group, with none of 
the SNPs being significantly associated with BMI in the control sample alone, and the 
association strengthening when analysing the patients alone. A similar pattern was found 
in the PsyCoLaus sample, strongly arguing against this being a chance finding. 
 
There are two potential limitations of our study. The first is in the Radiant sample self-
reported data were used to calculate BMI. Against this, height and weight were actually 
measured in the replication sample (PsyCoLaus) and the same pattern of results was 
found. The second limitation is that FTO polymorphism most frequently reported to be 
associated with BMI (rs9939609) in previous studies was here imputed rather than 
genotyped directly. Against this, the imputation was based on two genotyped SNPs 
(rs8050136, rs3751812) that are in absolute LD (r2=1) with rs9939609. 
 
In the Radiant study evidence that the observed FTO-BMI association is specific to the 
depressive sample is further supported by the interaction between FTO variants and 
affected status. This interaction was found in 7 of the SNPs associated with BMI and 
indicates that the failure to observe an association in the control sample is unlikely to be a 
consequence of a lack of power. This suggests that the effect of the FTO gene on BMI is 
modified by having a depressive disorder. Furthermore, the interaction between FTO 
variants and affected status found in the Radiant data was corroborated by the combined 
results obtained from the Radiant and PsyCoLaus samples. 
 
As this was the first study of its kind concerning the relationship between BMI and 
depression we decided to interrogate the entire FTO gene. However the evidence for the 
association with BMI was, as in previous studies not involved with depression, 
concentrated in a group of SNPs located in the first intron of the gene. Previous studies 
report association with SNPs located in the same region.6-10 Interestingly, 5 associated 
SNPs (rs6499640, rs8050136, rs3751812, rs7190492, rs8044769) in our sample have also 
been found to be genome-wide significantly associated with variation in BMI in the study 
by Thorleifsson et al.9 Two of the most significant SNPs associated with BMI in Radiant 
and PsyCoLaus studies (rs3751812, rs8050136) are in absolute LD (r2=1) with the FTO 
variant rs9939609. The results obtained with this imputed variant in both studies are in 
the same direction and confirm previous findings.6-8,33-37 
 
In the Radiant study depressed patients had higher BMI than controls and this could be 
attributable to a side effect of antidepressant treatment, or because of people who are 
depressed carry out less physical activity and/or have an increased food intake. These 
effects are impossible to tease apart in the Radiant sample because all of the cases had at 
some point received antidepressants. Also, our control sample has been screened so as to 
have no history of psychiatric disorder in themselves or a first-degree relative. This is 
something previous studies investigating BMI, obesity and FTO have not done and could 
further explain why no association is observed in our control group. 
 
In contrast, in the PsyCoLaus sample there were no statistically significant differences in 
BMI between depressed cases and controls. These differences possibly reflect the fact 
that Radiant is a clinically ascertained sample of mainly recurrent depression and all of 
the cases recruited have received antidepressant treatment, whereas the PsyCoLaus cases 
were recruited from the community and were an arguably less severe and more broadly 
defined group, where only one episode was required for inclusion and in which only 
37.5% of cases had ever received treatment with antidepressants. However, it is 
noteworthy that the regression of BMI on antidepressant status showed no hint of 
association (p = 0.573) nor was there any effect when antidepressant status was included 
as a covariate in the regression of BMI on FTO SNPs. These findings indicate that 
moderating effect of depressive disorder on the BMI/FTO association is unlikely to be 
simply a result of taking antidepressants. 
 
An alternative but not necessarily exclusive explanation is that depression and obesity 
involve pathophysiologically overlapping mechanisms. The hypothalamic-pituitary-
adrenocortical (HPA) system governs the stress response and has been implicated in the 
aetiology of depression.38 FTO is highly expressed in the hypothalamus, pituitary and 
adrenal glands indicating a possible role in the HPA axis which is involved in body 
weight regulation.39 
 
Although several studies have investigated the influence of FTO variants on BMI, and the 
association between obesity and psychiatric disorders separately, to the authors’ 
knowledge this is the first study investigating the relationship between FTO, BMI and 
psychiatric disorders (depression) concurrently. Our research suggests that although an 
association is observed in the whole sample, having a history of depression does in fact 
moderate the effect of FTO on BMI. The results found initially in the large clinical 
sample of depressed cases and controls (Radiant) have been replicated in a population-
based cohort (PsyCoLaus). In addition, since milder forms of depression and depressive 
symptoms are very common in the general population40 it is possible that experiencing 
such symptoms moderates the effect of FTO in the population as a whole and partly 
determines whom of those carrying ‘ at risk’ FTO variants go on to become overweight 
or obese. 
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Table 1. Demographic characteristics of the Radiant and PsyCoLaus samples. 
 










Sample size n=2442 n=809 n=1296 n=1698 
Gender (%) 
(male/female) 
30.3 / 69.7 38.7 / 61.3 33.49 / 66.51 57.36 / 42.64 
Mean age (years) 
± s.d 
45.25 ± 12.15 39.90 ± 13.71 49.69 ± 8.68 50.59 ± 8.94 
 
Mean BMI ± s.d. 
(male/female) 
 
26.62 ±4.32 / 
26.31±5.96 
 
25.18 ±4.31 / 
23.78±4.53 
 
26.04 ± 3.84 / 
24.83 ± 5.06 
 
26.39 ± 3.80 / 
24.86 ± 4.86 
 
Table 2. Association analyses between FTO and LogBMI and the interaction with 
affected status in the Radiant study.  
 
a Position (chr 16) according to the HapMap database. 
bRisk Alleles are underlined. 
c Interaction between FTO SNPs and affected status. 





SNP Positiona Alleleb MAF Combined Cases Controls Interactionc
rs7205986 52312647 A/G 0.48 (A) 0.0024 0.002 0.518 0.1641 
rs6499640 52327178 G/A 0.38 (G) 0.0006 0.0014 0.149 0.5219 
rs9930333 52357478 G/T 0.44 (G) 0.0032  0.0001  0.166 0.0014 
rs10852521 52362466 T/C 0.48 (T) 0.0016   7.5x10-5 0.272 0.0019 
rs8050136 52373776 A/C 0.41 (A) 0.0018  0.0001  0.317 0.0031 
rs3751812 52375961 T/G 0.41 (T) 0.0013  6.8x10-5 0.337 0.0028 
rs9941349 52382989 T/C 0.43 (T) 0.0013  7.4x10-5 0.399 0.0037 
rs7190492 52386253 A/G 0.37 (A) 0.0092    0.001 0.309 0.0057 
rs8044769 52396636 T/C 0.48 (T) 0.0011    7x10-5 0.454 0.0045 
Table 3.Association analyses between FTO and LogBMI and the interaction with affected 
status in the PsyCoLaus study. 
 p-values 
SNP Positiona Alleleb MAF Combined Cases Controls Interactionc 
rs9930333 52357478 G/T 0.44 (G) 0.00096  0.00066 0.1633 0.0640 
rs10852521 52362466 T/C 0.46 (T) 0.0856    0.136 0.3242 0.5468 
rs8050136 52373776 A/C 0.41 (A) 0.0047  0.00099 0.4063 0.0336 
rs3751812 52375961 T/G 0.41 (T) 0.0057  0.0014  0.4047 0.0408 
rs9939609 52378028 A/T 0.41 (A) 0.0058  0.0016  0.3915 0.0444 
rs9941349 52382989 T/C 0.43 (T) 0.0026  0.0010  0.2737 0.0530 
rs7190492 52386253 A/G 0.33 (A) 0.025     0.0164 0.4032 0.1390 
rs8044769 52396636 T/C 0.46 (T) 0.16    0.157 0.5371 0.4311 
 
a Position (chr 16) according to the HapMap database. 
bCoded Alleles are underlined. 
c Interaction between FTO SNPs and affected status.  







Table 4.Interaction analyses between FTO and affected status in the combined sample. 
 
SNP Positiona Coded Allele ß SE p-value 
rs9930333 52357478 G 0.01 0.0029 7x10-4 
rs10852521 52362466 T -0.007 0.0029 0.0199 
rs8050136 52373776 A 0.01 0.03 5x10-4 
rs3751812 52375961 T 0.01 0.03 6x10-4 
rs9939609 52378028 T -0.01 0.03 0.001 
rs9941349 52382989 T 0.01 0.029 0.001 
 
a Position (chr 16) according to the HapMap database. 



































































Supplementary Figure 1. LD plot structure for the most significant SNPs in FTO gene. 
Red represents very high LD (r2) between SNPs. 
 

